Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma.
Lopci E, Santi I, Tani M, Maffione AM, Montini G, Castellucci P, Stefoni V, Rubello D, Fonti C, Zinzani P, Fanti S. Lopci E, et al. Among authors: fonti c. Q J Nucl Med Mol Imaging. 2010 Aug;54(4):436-41. Epub 2010 May 27. Q J Nucl Med Mol Imaging. 2010. PMID: 20823812
FDG PET/CT predictive role in follicular lymphoma.
Lopci E, Zanoni L, Chiti A, Fonti C, Santi I, Zinzani PL, Fanti S. Lopci E, et al. Among authors: fonti c. Eur J Nucl Med Mol Imaging. 2012 May;39(5):864-71. doi: 10.1007/s00259-012-2079-y. Epub 2012 Feb 22. Eur J Nucl Med Mol Imaging. 2012. PMID: 22354449
(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C, Zanoni L, Pultrone C, Schiavina R, Brunocilla E, Lodi F, Malizia C, Ferrari M, Rigatti P, Fonti C, Martorana G, Fanti S. Nanni C, et al. Among authors: fonti c. Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1601-10. doi: 10.1007/s00259-016-3329-1. Epub 2016 Mar 10. Eur J Nucl Med Mol Imaging. 2016. PMID: 26960562 Clinical Trial.
[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial.
Zanoni L, Bianchi L, Nanni C, Pultrone C, Giunchi F, Bossert I, Matti A, Schiavina R, Fiorentino M, Romagnoli D, Fonti C, Lodi F, D'Errico A, Brunocilla E, Porreca A, Fanti S. Zanoni L, et al. Among authors: fonti c. Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):390-409. doi: 10.1007/s00259-021-05429-6. Epub 2021 Jul 2. Eur J Nucl Med Mol Imaging. 2021. PMID: 34213609 Clinical Trial.
The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis.
Zanoni L, Mei R, Bianchi L, Giunchi F, Maltoni L, Pultrone CV, Nanni C, Bossert I, Matti A, Schiavina R, Fiorentino M, Fonti C, Lodi F, D'Errico A, Brunocilla E, Fanti S. Zanoni L, et al. Among authors: fonti c. Cancers (Basel). 2021 Mar 29;13(7):1575. doi: 10.3390/cancers13071575. Cancers (Basel). 2021. PMID: 33805543 Free PMC article.
38 results